PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPosaconazole
Noxafil(posaconazole)
Noxafil, Posaconazole (posaconazole) is a small molecule pharmaceutical. Posaconazole was first approved as Noxafil on 2005-10-25. It is used to treat mycoses and oral candidiasis in the USA. It has been approved in Europe to treat aspergillosis, candidiasis, coccidioidomycosis, and mycoses.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
stomatognathic diseasesD009057
Trade Name
FDA
EMA
Noxafil, Posaconazole (discontinued: Noxafil, Posaconazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Posaconazole
Tradename
Company
Number
Date
Products
NOXAFILMerck & CoN-205596 RX2014-03-13
1 products, RLD, RS
NOXAFIL POWDERMIX KITMerck & CoN-214770 RX2021-05-31
1 products, RLD, RS
NOXAFILMerck & CoN-022003 RX2006-09-15
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
noxafilNew Drug Application2024-10-25
posaconazoleANDA2025-06-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
mycoses—D009181B35-B49
oral candidiasisEFO_0007406D002180B37.0
Agency Specific
FDA
EMA
Expiration
Code
POSACONAZOLE, NOXAFIL, MERCK SHARP DOHME
2028-06-17ODE-355
2024-06-17I-881
2024-05-31NPP
POSACONAZOLE, NOXAFIL POWDERMIX KIT, MSD MERCK CO
2024-05-31NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Posaconazole, Noxafil, Merck Sharp Dohme
94935822033-02-27DP
90237902031-07-04DPU-1698, U-3160, U-3171
93582972031-06-24DPU-3160, U-3171
84100772029-03-13DP
97508222029-03-13DP
101179512029-03-13DP
ATC Codes
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AC: Triazole and tetrazole derivatives
— J02AC04: Posaconazole
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181—B35-B495674628
Invasive fungal infectionsD000072742——4242416
InfectionsD007239EFO_0000544—4324215
Communicable diseasesD003141——4112210
AspergillosisD001228EFO_0007157B44—12216
Invasive pulmonary aspergillosisD055744—B44.0—111—3
CandidiasisD002177—B37—111—3
NeutropeniaD009503—D701—11—3
Myeloid leukemia acuteD015470—C92.0——11—2
Myeloid leukemiaD007951—C92——11—2
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190—D46—11——2
Hiv infectionsD015658EFO_0000764B20—11——2
Oral candidiasisD002180EFO_0007406B37.0—11——2
Pulmonary aspergillosisD055732EFO_1001834———1——1
LeukopeniaD007970EFO_0004233D72.819——1——1
CoccidioidomycosisD003047EFO_0007211B38——1——1
CoccidiosisD003048EFO_0007212———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnemiaD000740EFO_0004272D64.9—1———1
Aplastic anemiaD000741—D61.9—1———1
PreleukemiaD011289———1———1
SyndromeD013577———1———1
Chagas diseaseD014355EFO_0008559B57—1———1
LeukemiaD007938—C95—1———1
OnychomycosisD014009—B35.1—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung transplantationD016040——————11
Covid-19D000086382—U07.1————11
Respiratory tract infectionsD012141—J06.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePosaconazole
INNposaconazole
Description
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.
Classification
Small molecule
Drug classsystemic antifungals (miconazole type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
Identifiers
PDB—
CAS-ID171228-49-2
RxCUI—
ChEMBL IDCHEMBL1397
ChEBI ID64355
PubChem CID147912
DrugBankDB01263
UNII ID6TK1G07BHZ (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Noxafil – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Posaconazole
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 12,500 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,815 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use